Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma

Pamela B. Allen*, Jane Norma Winter

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. Summary: The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.

Original languageEnglish (US)
Article number39
JournalCurrent oncology reports
Volume21
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Hodgkin Disease
Therapeutics
Radiotherapy
Radiation

Keywords

  • Brentuximab vedotin
  • Checkpoint inhibitors
  • Hodgkin lymphoma
  • Immunotherapy
  • Nivolumab
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology

Cite this

@article{b120ea5a540d48628292c082f9f44f6d,
title = "Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma",
abstract = "Purpose of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. Summary: The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.",
keywords = "Brentuximab vedotin, Checkpoint inhibitors, Hodgkin lymphoma, Immunotherapy, Nivolumab, Pembrolizumab",
author = "Allen, {Pamela B.} and Winter, {Jane Norma}",
year = "2019",
month = "5",
day = "1",
doi = "10.1007/s11912-019-0788-0",
language = "English (US)",
volume = "21",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. / Allen, Pamela B.; Winter, Jane Norma.

In: Current oncology reports, Vol. 21, No. 5, 39, 01.05.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma

AU - Allen, Pamela B.

AU - Winter, Jane Norma

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. Summary: The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.

AB - Purpose of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. Summary: The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.

KW - Brentuximab vedotin

KW - Checkpoint inhibitors

KW - Hodgkin lymphoma

KW - Immunotherapy

KW - Nivolumab

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85063610373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063610373&partnerID=8YFLogxK

U2 - 10.1007/s11912-019-0788-0

DO - 10.1007/s11912-019-0788-0

M3 - Review article

VL - 21

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

M1 - 39

ER -